A phase III trial comparing CHOP to PMitCEBO with or without G-CSF in patients aged 60 plus with aggressive non-Hodgkin's lymphoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A phase III trial comparing CHOP to PMitCEBO with or without G-CSF in patients aged 60 plus with aggressive non-Hodgkin's lymphoma

Published:2006-02-28 Issue:6 Volume:94 Page:806-813
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Burton C,Linch D,Hoskin P,Milligan D,Dyer M J S,Hancock B,Mouncey P,Smith P,Qian W,MacLennan K,Jack A,Webb A,Cunningham D

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/6602975.pdf

Reference34 articles.

1. Armitage J, Potter J (1984) Aggressive chemotherapy for diffuse histiocytic lymphoma in the elderly: increased complications with advancing age. J Am Geriatr Soc 32: 269–273

2. Balducci L, Lyman G, Ozer H (2001) Patients aged {⩾} 70 are at high risk for neutropenic infection and should receive hemopoietic growth. J Clin Oncol 19: 1583–1585

3. Bastion Y, Blay JY, Divine M, Brice P, Bordessoule D, Sebban C, Blanc M, Tilly H, Lederlin P, Deconinck E, Salles B, Dumontet C, Briere J, Coiffier B (1997) Elderly patients with aggressive non-Hodgkin's lymphoma: disease presentation, response to treatment, and survival – a Groupe d'Etude des Lymphomes de l'Adulte study on 453 patients older than 69 years. J Clin Oncol 15: 2945–2953

4. Bertini M, Freilone R, Vitolo U Botto B, Pizzuti M, Gavarotti P, Levis A, Orlandi E, Orsucci L, Pini M (1994) P-VEBEC: a new 8-weekly schedule with or without rG-CSF for elderly patients with aggressive non-Hodgkin's lymphoma. Ann Oncol 5: 895–900

5. 2001 Census (2001) Office of Population Censuses and Surveys. London, UK: Her Majesty's Stationery Office

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic Management of Lymphoma: Conventional Strategies and Overcoming Treatment Barriers with Nanotherapeutics;Current Cancer Therapy Reviews;2023-05

2. Prognostic value of interim FDG PET-CT in patients older than 60 years with diffuse large B-cell lymphoma treated by PMitCEBO plus rituximab. Comparison between Deauville 5-point scale and International Harmonization Project criteria;The Quarterly Journal of Nuclear Medicine and Molecular Imaging;2022-02

3. Developments over the last 60 years in diffuse large B‐cell lymphomas;British Journal of Haematology;2020-11

4. Clinical Response and Adverse Event Profile of Bleomycin Chemotherapy for Canine Multicentric Lymphoma;Journal of the American Animal Hospital Association;2017-03-01

5. Efficacy and toxicity of PACEBOM chemotherapy in relapsed/refractory aggressive lymphoma in the rituximab era;Asia-Pacific Journal of Clinical Oncology;2016-12-22

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3